Evidence map›Paper›PMID 36172021›Full record

ReviewFrontiers in bioengineering and biotechnology2022

Applications of phase change materials in smart drug delivery for cancer treatment.

Jianfeng Bao, Hui Tu, Jing Li, Yijia Li, Shan Yu, Jingpi Gao, Kun Lei, Fengshou Zhang, Jinghua Li

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Spatiotemporal cancer controlNanomedicine (London, England) · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jianfeng BaoSchool of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, China.
Hui TuSchool of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, China.
Jing LiOffice of Science & Technology, Henan University of Science and Technology, Luoyang, China.
Yijia LiSchool of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, China.
Shan YuSchool of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, China.
Jingpi GaoSchool of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, China.
Kun LeiSchool of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, China.
Fengshou ZhangSchool of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, China.
Jinghua LiSchool of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, China.
Henan University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phase change materials (PCMs) are materials that are stimulated by the external enthalpy change (temperature) to realize solid-liquid and liquid-solid phase transformation. Due to temperature sensitivity, friendly modification, and low toxicity, PCMs have been widely used in smart drug delivery. More often than not, the drug was encapsulated in a solid PCMs matrix, a thermally responsive material. After the trigger implementation, PCMs change into a solid-liquid phase, and the loading drug is released accordingly. Therefore, PCMs can achieve precise release control with different temperature adjustments, which is especially important for small molecular drugs with severe side effects. The combination of drug therapy and hyperthermia through PCMs can achieve more accurate and effective treatment of tumor target areas. This study briefly summarizes the latest developments on PCMs as smart gate-keepers for anti-tumor applications in light of PCMs becoming a research hot spot in the nanomedicine sector in recent years.

Indexed as

controlled releasedrug deliverydrug encapsulationPCMsthermochemical therapy

Identifiers

PMID36172021
PMCPMC9510677
OpenAlexW4296524203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.